Exelixis, Bristol-Myers mount pivotal study of Cabo/Opdivo combo for frontline kidney cancer
Just days after reviewing a promising start combining Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) with Cabometyx (cabozantinib), Exelixis is rolling out a late-stage partnership that will take the combo into a pivotal Phase III study as a frontline therapy for kidney cancer. And not satisfied with the one checkpoint tie-up, the South San Francisco-based biotech also announced a deal this morning to collaborate with Roche on a combination of its drug Tecentriq (atezolizumab) and cabo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.